Kura Oncology (NASDAQ:KURA) Earns "Outperform" Rating from Wedbush

Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities research analysts at Wedbush in a report issued on Tuesday,RTT News reports. They currently have a $36.00 target price on the stock.

Other equities research analysts have also issued research reports about the company. UBS Group decreased their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. Scotiabank reduced their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Finally, StockNews.com raised Kura Oncology from a "hold" rating to a "buy" rating in a report on Friday, April 4th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $25.50.

Kura Oncology Stock Performance

Kura Oncology stock traded up $0.14 during mid-day trading on Tuesday, reaching $5.77. 2,111,548 shares of the company's stock were exchanged, compared to its average volume of 1,123,108. The firm has a market capitalization of $465.96 million, a PE ratio of -2.44 and a beta of 0.83. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The business's fifty day simple moving average is $7.36 and its 200 day simple moving average is $10.86. Kura Oncology has a one year low of $5.41 and a one year high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, sell-side analysts expect that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company's stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 over the last ninety days. Insiders own 5.50% of the company's stock.

Institutional Trading of Kura Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its position in Kura Oncology by 5.2% during the 1st quarter. Rhumbline Advisers now owns 105,206 shares of the company's stock valued at $694,000 after buying an additional 5,215 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Kura Oncology by 7.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company's stock worth $1,147,000 after purchasing an additional 9,050 shares during the period. Woodline Partners LP grew its stake in shares of Kura Oncology by 20.6% in the fourth quarter. Woodline Partners LP now owns 172,704 shares of the company's stock worth $1,504,000 after purchasing an additional 29,497 shares during the last quarter. Velan Capital Investment Management LP purchased a new position in Kura Oncology during the 4th quarter valued at about $1,306,000. Finally, Squarepoint Ops LLC bought a new position in Kura Oncology during the 4th quarter valued at approximately $799,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.